Loading...
•
Jun 30, 2021
NeoGenomics Q2 2021 Earnings Report
NeoGenomics reported strong second-quarter results with significant year-over-year growth across all three divisions and strategic position strengthened through acquisitions.
Key Takeaways
NeoGenomics reported a 40% increase in consolidated revenue, reaching $122 million in the second quarter of 2021. The company's clinical services revenue grew by 37% to $101 million, while pharma services revenue increased by 55% to $20 million. The company also completed the acquisitions of Trapelo Health and Inivata Limited during the quarter.
Consolidated revenue increased 40% to $122 million.
Clinical Services revenue increased 37% to $101 million.
Pharma Services revenue increased 55% to $20 million.
Completed acquisitions of Trapelo Health and Inivata Limited.
Forward Guidance
The Company reiterated its full-year 2021 guidance, initially issued on May 5, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...